Granulocyte Colony-Stimulating Factor (G-CSF) – Simoa

Granulocyte Colony-Stimulating Factor (G-CSF)

Ultrasensitive Immunoassay

Rules-Based Medicine’s (RBM) internally developed and manufactured ultrasensitive immunoassay to granulocyte-colony stimulating factor (G-CSF) based on the Simoa® bead technology can accurately quantitate sub-pg/mL levels of G-CSF in human serum and plasma. Such sensitive G-CSF detection is useful for clinical studies in neutropenia, cancer chemotherapy, neurologic, cardiovascular, and autoimmune diseases.

Granulocyte-colony stimulating factor (G-CSF) is a growth factor produced by endothelial cells, macrophages, fibroblast, bone marrow stromal cells and other immune cells. The G-CSF receptor (G-CSFR) is expressed on myeloid progenitors and endothelial cells. G-CSF stimulates production and mobilization of neutrophils and regulates survival, proliferation, and differentiation of various cells of the neutrophil lineage. Importantly, G-CSF can also mobilize CD34+ stem cells from bone marrow to peripheral blood. Under normal physiological conditions, circulating levels of G-CSF are low in contrast to infection, tissue injury, inflammation, or other stress and pathological conditions. Recombinant G-CSF is used to treat neutropenia and chemotherapy-associated neutropenia.

Swiss-Prot Accession Number: P09919

* Lower limit of quantitation (LLOQ) represents the lowest amount of an analyte that can be quantitatively determined with acceptable precision. LLOQ is determined by performing 2-fold serial dilutions of Standard to be tested in triplicate over three runs. The percent coefficient of variation (CV) is calculated for each of the dilution replicates, and the LLOQ is determined as the concentration at which the CV is 30%.

** Cerebrospinal fluid, urine, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

All assay services are performed in our CLIA-certified laboratory.
Intended for Research Use Only.